Novo Nordisk Earnings Beat Estimates; Guidance Up

Danish drugmaker Novo Nordisk (NVO) beat analysts' Q3 expectations and raised its full-year profit guidance early Wednesday. The company's U.S. shares were down a fraction in midday trading. The company, which makes insulin and other diabetes treatments, reported sales of 19.9 billion kroner, a hair over the Bloomberg consensus of 19.8 billion and up 20% from the year-ago quarter. In U.S. ...

Technology is a subscriber feature. Take a free trial now to get instant access.

Try the Digital + Weekly Print Combo and enjoy the best of both worlds!eIBD is available after market close to give you a head start on the next day's market action. Plus, you get the Weekly Special print edition delivered right to your home or office!

Select market data is provided by Interactive Data Corp. Real Time Services. Price and Volume data is delayed 20 minutes unless otherwise noted, is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services terms. All times are Eastern United States. *Reflects real-time index prices.